The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17).
 
Naoto Kondo
No Relationships to Disclose
 
Yoshinori Ito
Consulting or Advisory Role - Novartis
Speakers' Bureau - Chugai Pharma; Eisai; Novartis
Research Funding - Chugai Pharma; Daiichi Sankyo; Eisai; Novartis; Parexel; Taiho Pharmaceutical
 
Ippei Fukada
No Relationships to Disclose
 
Shoichiro Ohtani
No Relationships to Disclose
 
Masaya Hattori
Honoraria - Chugai Pharma; Eisai; Novartis
 
Eriko Tokunaga
No Relationships to Disclose
 
Nobuki Matsunami
No Relationships to Disclose
 
Kohjiro Mashino
No Relationships to Disclose
 
Taijiro Kosaka
No Relationships to Disclose
 
Masahiko Tanabe
No Relationships to Disclose
 
Daisuke Yotsumoto
No Relationships to Disclose
 
Kosho Yamanouchi
No Relationships to Disclose
 
Masataka Sawaki
No Relationships to Disclose
 
Masahiro Kashiwaba
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Kirin Pharmaceuticals; Pfizer; Sanofi
Research Funding - Chugai Pharma
 
Hidetaka Kawabata
No Relationships to Disclose
 
Katsumasa Kuroi
No Relationships to Disclose
 
Satoshi Morita
Honoraria - Chugai Pharma
Consulting or Advisory Role - Chugai Pharma
 
Shinji Ohno
No Relationships to Disclose
 
Masakazu Toi
Research Funding - Eisai
 
Norikazu Masuda
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Hakko Kirin
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Novartis (Inst)